Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Gemcitabine and Radiation for Soft Tissue Sarcoma
NCT02046304Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2001
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gemcitabine in soft tissue sarcoma (STS), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose of Preoperative Gemcitabine with External-Beam Radiation Therapy at 6 weeks. Started Dec 2001; status: completed.
02
Drugs
gemcitabine
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02046304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02046304.